ONO-4538 Phase II/III Study A Multicenter, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer

Trial Profile

ONO-4538 Phase II/III Study A Multicenter, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Nivolumab (Primary) ; Capecitabine; Gimeracil/oteracil/tegafur; Oxaliplatin
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms ATTRACTION-04
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 12 Sep 2017 Interim results (n=40) from part-I of the study assessing safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction cancer, presented at the 42nd European Society for Medical Oncology Congress
    • 08 Sep 2017 According to trial design presented at the 42nd European Society for Medical Oncology Congress, part 2 of this study was started in February 2017
    • 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top